How big is Amicus Therapeutics, Inc.?

As of Jun 18, Amicus Therapeutics, Inc. has a market capitalization of $1.786 billion, with net sales of $543.15 million and a net profit of -$29.38 million over the latest four quarters. The company reported shareholder's funds of $194.04 million and total assets of $785.03 million as of Dec 24.

Market Cap: As of Jun 18, Amicus Therapeutics, Inc. has a market capitalization of 1,786.00 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Amicus Therapeutics, Inc. reported net sales of 543.15 million and a net profit of -29.38 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 194.04 million and total assets of 785.03 million.

What does Amicus Therapeutics, Inc. do?

Amicus Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare metabolic diseases, with a market capitalization of approximately $1.79 billion. As of March 2025, it reported net sales of $125 million and a net loss of $22 million.

Overview: <BR>Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases, operating in the Pharmaceuticals & Biotechnology industry with a small-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 125 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,786.00 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.77 <BR>Return on Equity: -13.55% <BR>Price to Book: 9.23<BR><BR>Contact Details: <BR>Address: 1 Cedarbrook Dr, CRANBURY NJ: 08512-3618 <BR>Tel: 1 609 6622000 <BR>Fax: 1 609 6622001 <BR>Website: http://www.amicusrx.com

Who are in the management team of Amicus Therapeutics, Inc.?

As of March 2022, the management team of Amicus Therapeutics, Inc. includes Chairman and CEO John Crowley, President and COO Bradley Campbell, and several independent directors: Michael Raab, Lynn Bleil, Robert Essner, Michael Kelly, and Margaret McGlynn.

As of March 2022, the management team of Amicus Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. John Crowley, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Bradley Campbell, who is the President, Chief Operating Officer, and a Director.<BR>- Mr. Michael Raab, who holds the position of Lead Independent Director.<BR>- Ms. Lynn Bleil, who is an Independent Director.<BR>- Mr. Robert Essner, who is also an Independent Director.<BR>- Mr. Michael Kelly, who serves as an Independent Director.<BR>- Ms. Margaret McGlynn, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Crowley and Mr. Campbell in key operational roles.

Should I buy, sell or hold Amicus Therapeutics, Inc.?

Is Amicus Therapeutics, Inc. overvalued or undervalued?

As of November 7, 2016, Amicus Therapeutics, Inc. is considered risky and overvalued compared to its peers, with a high Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, while its stock has underperformed over the year with a return of -9.98% compared to the S&P 500's 12.22%.

As of 7 November 2016, the valuation grade for Amicus Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued, as evidenced by its Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, which are significantly higher than many of its peers. In comparison, Alkermes Plc, which is rated attractive, has a much lower EV to EBITDA of 9.4080, while Ionis Pharmaceuticals, Inc. also shows a risky valuation with an EV to EBITDA of -37.8563.<BR><BR>The stock has experienced mixed performance, with a one-week return of 5.74% compared to the S&P 500's 1.05%, but it has significantly underperformed over longer periods, including a year-to-date return of -9.98% versus the S&P 500's 12.22%. This trend reinforces the notion that Amicus Therapeutics, Inc. is overvalued relative to its peers and the broader market.

Is Amicus Therapeutics, Inc. technically bullish or bearish?

As of October 10, 2025, Amicus Therapeutics, Inc. shows a mildly bullish trend with positive indicators like a bullish MACD and moving averages, but caution is warranted due to bearish monthly signals and underperformance over the year.

As of 10 October 2025, the technical trend for Amicus Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe, bullish Bollinger Bands on the weekly, and a bullish daily moving average. However, the monthly MACD and KST remain bearish, indicating some caution. The RSI is bearish on the weekly but shows no signal on the monthly, adding to the mixed signals. <BR><BR>In terms of performance, the stock has returned 2.38% over the past month, outperforming the S&P 500's 0.31%, but it has significantly underperformed over longer periods, with a year-to-date return of -13.16% compared to the S&P 500's 11.41%. Overall, while there are some bullish indicators, the longer-term performance remains concerning.